<DOC>
	<DOCNO>NCT01653236</DOCNO>
	<brief_summary>Hypothesis Combination Boceprevir Ribavirin treatment-naïve patient genotype 4 chronic hepatitis C infection increase proportion patient achieve sustained viral response compare standard treatment alone .</brief_summary>
	<brief_title>Boceprevir With Peginterferon Alfa-2b Ribavirin Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection</brief_title>
	<detailed_description>Objectives : The primary objective study assess efficacy safety Boceprevir 800 mg three time per day ( TID ) orally ( PO ) ( hereafter call Boceprevir ) combination peginterferon alfa-2b 1.5 μg/kg per week ( QW ) subcutaneously ( SC ) plus weight-based dosing ( WBD ) ribavirin ( 800 1400 mg/day ) compare standard care ( SOC ) ( therapy peginterferon alfa-2b ( PEG ) +ribavirin ( RBV ) WBD ) previously untreated adult subject chronic hepatitis C ( CHC ) genotype 4 infection . Primary Trial Objectives : - The primary efficacy objective study ass efficacy Boceprevir combination PEG 1.5 μg/kg QW SC plus WBD RBV ( 800 1400 mg/day ) compare efficacy SOC ( therapy PEG+RBV WBD ) Control Arm previously untreated adult subject CHC genotype 4 infection</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Ages Eligible Study : 18 Years old Genders Eligible Study : Both Subject must 18 year age . Subject 's weight must 40 kg less 125 kg . Subject subject 's partner must agree use acceptable method contraception least 2 week prior Day 1 continue least 6 month last dose study medication , longer dictate local regulation . Subjects must willing give write informed consent trial pharmacogenetic testing . Subjects unwilling provide write informed consent pharmacogenetic testing may include trial ; however , pharmacogenetic sample must obtain . Subject must previously document CHC genotype 4 infection . Subjects mixed genotype eligible . The HCVRNA result obtain central laboratory screen visit must confirm genotype 4 infection more10,000 IU per mL Previously untreated patient Pegylated interferon Subject must liver biopsy fibrotest fibroscan histology consistent CHC etiology . Subject coinfected human immunodeficiency virus ( HIV ) hepatitis B virus . Prior treatment interferon , ribavirin and/or investigational agent hepatitis C. Prior treatment herbal remedy know hepatotoxicity exclusionary . All herbal remedy use hepatitis C treatment must discontinue Day 1 . Treatment investigational drug within 30 day screen visit trial . Subject receive following medication ( ) within 2 week prior Day 1 visit highly dependent CYP3A4.5 clearance , elevate plasma concentration associate serious lifethreatening event : orally administer midazolam , pimozide , amiodarone , flecainide , propafenone , quinidine ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) . Evidence decompensated liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>